Citadel Advisors
SGTX

Citadel Advisors’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Citadel Advisors’s Portfolio SGTX Stock Details SGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-54
Closed -$651 – 15689
2023
Q1 		$651 Buy
+54
New +$561 ﹤0.01% 14446
2021
Q4 		– Sell
-1,085
Closed -$80K – 15161
2021
Q3 		$80K Buy
+1,085
New +$83.5K ﹤0.01% 13076

Other funds holding SGTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors's SGTX Position: Q1 2023 in Review

Citadel Advisors sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q1 2023, closing a stake of 2,575 shares — an estimated $26.7K sold.

Citadel Advisors first reported a position in SGTX in Q1 2021 and held it in 5 quarters. The position peaked at $204K in Q1 2021. 32 funds tracked by Wall St. Rank hold SGTX as of Q1 2023.

  • Citadel Advisors reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Citadel Advisors sold 2,575 Sigilon Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $26.7K.
  • Citadel Advisors first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Citadel Advisors's Sigilon Therapeutics, Inc. Common Stock position peaked at $204K in Q1 2021.
  • 32 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.